Proactiveinvestors United Kingdom Silence Therapeutics PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Silence Therapeutics PLC RSS feed en Thu, 20 Jun 2019 02:31:46 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190619091624_14116524/ Wed, 19 Jun 2019 09:16:24 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190619091624_14116524/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618163717_14115594/ Tue, 18 Jun 2019 16:37:17 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618163717_14115594/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618133740_14115381/ Tue, 18 Jun 2019 13:37:40 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618133740_14115381/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618122820_14115307/ Tue, 18 Jun 2019 12:28:20 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190618122820_14115307/ <![CDATA[News - Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments ]]> https://www.proactiveinvestors.co.uk/companies/news/221010/silence-therapeutics-given-access-to-genetic-database-in-its-bid-to-find-new-breakthrough-treatments-221010.html Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.

Genomics England has whole sequencing data on 100,000 genomes.

A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.

It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.

Data mining exercise 

In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.

Under the terms of the deal with Genomics England, Silence will “data mine” a subset of the information to focus on rare diseases and cardio-metabolic illnesses.

It wants to find disease-modifying target genes best suited to its unique technology.

The exercise should also help with “patient stratification” (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.

“This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.

]]>
Tue, 28 May 2019 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221010/silence-therapeutics-given-access-to-genetic-database-in-its-bid-to-find-new-breakthrough-treatments-221010.html
<![CDATA[RNS press release - Collaboration with Genomics England ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190528070011_14088091/ Tue, 28 May 2019 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190528070011_14088091/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190520164613_14080711/ Mon, 20 May 2019 16:46:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190520164613_14080711/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190514150007_14073677/ Tue, 14 May 2019 15:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190514150007_14073677/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190430070019_14056386/ Tue, 30 Apr 2019 07:00:19 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190430070019_14056386/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190426143558_14054065/ Fri, 26 Apr 2019 14:35:58 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190426143558_14054065/ <![CDATA[RNS press release - Additional Listing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190425165536_14052511/ Thu, 25 Apr 2019 16:55:36 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190425165536_14052511/ <![CDATA[News - Silence Therapeutics says Iain Ross to return as its chairman and non-executive director with immediate effect ]]> https://www.proactiveinvestors.co.uk/companies/news/219073/silence-therapeutics-says-iain-ross-to-return-as-its-chairman-and-non-executive-director-with-immediate-effect-219073.html Silence Therapeutics PLC (LON:SLN) shares rose on Thursday following news it has appointed Iain Ross as a non-executive director and its chairman with immediate effect, with the experienced director returning to a role he held from 2005 to 2010.

The AIM-listed group, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, pointed out that Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years.

READ: Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

Currently, it added, he is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma Plc.

Dr. David Horn Solomon, Silence’s chief executive officer commented: “Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers.”

Incoming chairman Ross added: "I am delighted to be returning to Silence Therapeutics and I look forward to working with David, the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the Board to deliver on its potential."

Silence also announced the appointment of James Ede-Golightly as a non-executive director, while it said Stephen Parker will step down from that role, both with immediate effect.

Ede-Golightly is currently chairman of DeepMatter Group PLC and Oxford Advanced Surfaces Ltd and a non-executive director at Oxehealth Limited.

In a note to clients, analysts at ‘house’ broker Peel Hunt pointed out that  today’s announcements follow other recent changes to Silence’s management and the board. 

“As a reminder of other recent appointments at Silence, Rob Quinn was appointed CFO from his role as interim CFO (18th April) and Giles Campion was appointed (16th April) Head of R&D and Chief Medical Officer (previously SVP of R&D at Prosena and holding senior roles at Novartis and Albumedix),” they said.

Peel Hunt continues to have its rating and target price for Silence ‘under review’.

In afternoon trading, the shares were 4.3% higher at 73p.

 -- Adds analyst comment, share price -- 

]]>
Thu, 25 Apr 2019 07:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219073/silence-therapeutics-says-iain-ross-to-return-as-its-chairman-and-non-executive-director-with-immediate-effect-219073.html
<![CDATA[RNS press release - Silence Therapeutics Announces Board Changes ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190425070008_14051042/ Thu, 25 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190425070008_14051042/ <![CDATA[News - Silence Therapeutics confirms Dr Rob Quinn as chief financial officer ]]> https://www.proactiveinvestors.co.uk/companies/news/218820/silence-therapeutics-confirms-dr-rob-quinn-as-chief-financial-officer-218820.html Silence Therapeutics PLC (LON:SLN) has given interim chief financial officer (CFO) Rob Quinn the job on a permanent basis.

Quinn has been the interim CFO since January 2019, having been the head of Financial Planning and Analysis at the company for the two years prior to getting the CFO gig.

READ Silence Therapeutics makes key new hire

“Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future," said David Horn Solomon, the chief executive officer of the AIM-listed drugs developer.

 

]]>
Thu, 18 Apr 2019 07:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218820/silence-therapeutics-confirms-dr-rob-quinn-as-chief-financial-officer-218820.html
<![CDATA[RNS press release - Appointment of Chief Financial Officer ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190418070008_14045569/ Thu, 18 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190418070008_14045569/ <![CDATA[RNS press release - Silence Therapeutics Publication of Annual Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190418070003_14045484/ Thu, 18 Apr 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190418070003_14045484/ <![CDATA[Media files - Silence Therapeutics accelerating into the clinic ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13040/silence-therapeutics-accelerating-into-the-clinic-13040.html Wed, 17 Apr 2019 15:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13040/silence-therapeutics-accelerating-into-the-clinic-13040.html <![CDATA[RNS press release - Silence Therapeutics Announces Board Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190416110002_14043001/ Tue, 16 Apr 2019 11:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190416110002_14043001/ <![CDATA[News - Silence Therapeutics makes key new hire ]]> https://www.proactiveinvestors.co.uk/companies/news/218656/silence-therapeutics-makes-key-new-hire-218656.html Silence Therapeutics PLC (LON:SLN) has appointed industry veteran Giles Campion as head of research and development and the company’s chief medical officer.

He occupied the same roles at Prosensa, which was acquired by Biomarin in 2015 for US$680mln and, in his 20-year career, he also held senior R&D roles at the Swiss giant Novartis (NYSE:NVS). He holds a medical degree and doctorate from Bristol University.

READ: Silence Therapeutics makes clinical trial application for lead drug

“Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions," said Silence chief executive David Horn Solomon.

Campion joins the company on June 1

In a later announcement, Silence also said the search for a permanent chairman continues after announcing that interim chair, Dr Andy Richards, had stepped down with immediate effect.

 -- Adds chairman's departure --

]]>
Tue, 16 Apr 2019 08:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218656/silence-therapeutics-makes-key-new-hire-218656.html
<![CDATA[RNS press release - Silence Therapeutics appoints Head of R&D and CMO ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190416070015_14042111/ Tue, 16 Apr 2019 07:00:15 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190416070015_14042111/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190404090932_14028812/ Thu, 04 Apr 2019 09:09:32 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190404090932_14028812/ <![CDATA[News - Silence Therapeutics makes clinical trial application for lead drug ]]> https://www.proactiveinvestors.co.uk/companies/news/217305/silence-therapeutics-makes-clinical-trial-application-for-lead-drug-217305.html Silence Therapeutics PLC (LON:SLN) has made a clinical trial application for its lead candidate, which is being developed to treat iron overload disorders.

SLN124 already has orphan drug designation in Europe, which could shorten its timeline to market while providing the approved product with additional exclusivity.

“Promising candidate medicine”

Silence describes SLN124 as a “promising candidate medicine” for patients with iron overload disorders such as ß -Thalassemia, Myelodysplastic Syndrome and Hereditary Hemochromatosis.

A phase Ib, first-in-human trial is scheduled to start in the third quarter.

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as Silence continued preparations for its return to the clinic.

“With robust data generated in several preclinical disease models, favourable safety profile and patient-friendly administration, we believe that SLN124 is well positioned against the current standard of care and other medicines in development for the treatment of iron overload disorders.”

]]>
Wed, 27 Mar 2019 08:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217305/silence-therapeutics-makes-clinical-trial-application-for-lead-drug-217305.html
<![CDATA[RNS press release - Silence Therapeutics submits CTA for SLN124 ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190327070004_14016897/ Wed, 27 Mar 2019 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190327070004_14016897/ <![CDATA[News - Silence Therapeutics gearing up for “exciting” year ]]> https://www.proactiveinvestors.co.uk/companies/news/216157/silence-therapeutics-gearing-up-for-exciting-year-216157.html Silence Therapeutics PLC (LON:SLN) bosses are looking forward to what should be an “exciting” nine months or so for the drug developer.

The company, which makes drugs that can ‘silence’ faulty genes, expects to begin its first-ever in-human trial in the second half of 2019 as it puts its SLN124 blood disorder treatment through its paces.

READ: Silence looks to clinical trials now patent dispute is over

Away from the flagship SLN124 drug, Silence is also carrying out pre-clinical work on its SLN360 cardiovascular disease treatment and it started investigational new drug (IND) enabling studies last month.

Data from this will support an IND application further down the line, which firms need if they wish to start human trials.

Silence’s QPI-1002 programme has been out-licensed to California-based Quark Pharmaceuticals, which kicked off a phase III trial in acute kidney injury patients last July.

Alnylam settlement

As well as all the progress in the lab, the company, which welcomed new boss David Horn Solomon last summer, has also recently scored a big victory in the courtroom.

Silence had been in a long-running dispute with US giant Alnylam which it claimed had ‘borrowed’ some of its intellectual property.

A settlement and license agreement were struck just before Christmas and Silence will receive a small tiered royalty on net sales of the US biotech group’s ONPATTRO drug in the EU.

Protecting its IP cost the company £4.0mln in 2018, which led to full-year losses widening to £18.4mln compared to a £1.6mln loss a year earlier when it benefited from the sale of its stake in US biopharma Arrowhead Pharmaceuticals.

Cash and cash equivalents stood at £26.5mln at the end of the year (2017: £42.7mln).

‘Defining year’

“2018 was a defining year for Silence Therapeutics, with transformational change throughout the business,” said chief executive David Horn Solomon.

“With the first RNAi therapeutics now approved by the FDA, effectively creating a new class of medicines, we are working hard to consolidate our position as a leading developer in this exciting new field.”

He added: “During the year we have made great progress in advancing our lead product SLN124 towards the clinic and we are due to commence in-human clinical trials later in 2019 to demonstrate safety and tolerability.”

]]>
Mon, 11 Mar 2019 07:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216157/silence-therapeutics-gearing-up-for-exciting-year-216157.html
<![CDATA[RNS press release - 2018 Preliminary Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190311070008_13996469/ Mon, 11 Mar 2019 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190311070008_13996469/ <![CDATA[RNS press release - Silence to Present at Cowen Healthcare Conference ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190307070028_13993239/ Thu, 07 Mar 2019 07:00:28 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190307070028_13993239/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190305070029_13989896/ Tue, 05 Mar 2019 07:00:29 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190305070029_13989896/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190304153526_13989524/ Mon, 04 Mar 2019 15:35:26 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190304153526_13989524/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190226172451_13982606/ Tue, 26 Feb 2019 17:24:51 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190226172451_13982606/ <![CDATA[News - Silence Therapeutics looks to clinical trial now patent dispute is out of the way ]]> https://www.proactiveinvestors.co.uk/companies/news/215128/silence-therapeutics-looks-to-clinical-trial-now-patent-dispute-is-out-of-the-way-215128.html The name provides a hint. It is a specialist in the field of gene silencing. Its technology uses RNA interference, a biological process in which RNA molecules inhibit gene expression or translation, by neutralising targeted molecules.

Pipeline

The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use. The pipeline as it stands is pre-clinical. It expects to kick off its first-in-human trial in the second half of this year on SLN124. Silence describes it as a “highly promising” treatment for genetic conditions such as β-Thalassemia, a rare blood disorder.

In January it was granted orphan drug designation for SLN124. The European Medicines Agency has concluded it will be of “significant benefit” to people affected by β-Thalassemia.

Orphan drug status gives drug makers – in this case, Silence – certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive.

For example, it can be easier to gain marketing approval for that drug or extend the exclusivity periods, while there are often also financial advantages such as tax breaks and R&D grants.

Without these incentives, companies might not pursue a drug’s development because the R&D costs would be too expensive.

The next drug in Silence’s pipeline is SLN226, which has shown potential to aid abstinence in people with alcohol dependency. It is in preclinical development at the moment, with plans in place for it to enter clinical trials in 2020.

Patent settlement

After a long-running wrangle with an American company Alnylam Pharmaceuticals, which was claimed have ‘borrowed’ some of Silence’s intellectual property, a settlement and licence agreement was brokered. Silence will receive a small tiered royalty on net sales of the US biotech group’s ONPATTRO drug in the EU.

What the broker says

“We see today’s [Alnylam] news as further validation of the competence that Silence has in RNAi therapeutics,” said Peel Hunt recently.

]]>
Fri, 22 Feb 2019 10:53:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215128/silence-therapeutics-looks-to-clinical-trial-now-patent-dispute-is-out-of-the-way-215128.html
<![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190201164049_13956080/ Fri, 01 Feb 2019 16:40:49 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190201164049_13956080/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190201163551_13956073/ Fri, 01 Feb 2019 16:35:51 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190201163551_13956073/ <![CDATA[News - Silence Therapeutics higher as lead medicine candidate granted orphan drug status ]]> https://www.proactiveinvestors.co.uk/companies/news/212556/silence-therapeutics-higher-as-lead-medicine-candidate-granted-orphan-drug-status-212556.html Silence Therapeutics PLC’s (LON:SLN) shares rose on Tuesday after the firm revealed that its lead candidate SLN124 has been granted orphan drug designation by European regulators.

The European Medicines Agency has concluded that SLN124 will be of “significant benefit” to people affected by β-Thalassemia – an inherited and potentially life-threatening blood disorder.

READ: Silence finance chief departs

In early studies, SLN124 was shown to lower serum iron levels and modulate tissue iron distribution in rodent models of β-Thalassemia and hereditary hemochromatosis.

“We are pleased to receive Orphan Drug Designation for our iron overload disorder candidate, SLN124, which will assist in expediting clinical development as we progress our Phase Ib trial planned to begin in H2 2019,” said chief executive David Horn Solomon.

“We believe that this innovative product offers significant promise for patients with iron overload disorders such as β-Thalassemia, MDS and hereditary hemochromatosis and we look forward to rapidly advancing SLN124 through clinical development.”

What is orphan drug status?​

Orphan drug status gives drugmakers – in this case, Silence– certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive.

For example, it can be easier to gain marketing approval for that drug or extend the exclusivity periods, while there are often also financial advantages such as tax breaks and R&D grants.

Without these incentives, companies might not pursue a drug’s development because the R&D costs would be too expensive.

Shares push higher

In a note to clients, analysts at Peel Hunt said today’s move was “a further sign of Silence’s commitment to progressing its pipeline”.

The City broker noted that it continues to have its rating and target price for Silence Therapeutics ‘under review’ as it assesses its model and valuation approach for the company following its recent litigation resolution.

In afternoon trading, shares in Silence Therapeutics were 7.4% higher at 56.80p.

 -- Adds analyst comment, share price --

]]>
Tue, 15 Jan 2019 07:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212556/silence-therapeutics-higher-as-lead-medicine-candidate-granted-orphan-drug-status-212556.html
<![CDATA[RNS press release - SLN124 granted Orphan Drug Designation by EMA ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190115070005_13934355/ Tue, 15 Jan 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190115070005_13934355/ <![CDATA[News - Silence Therapeutics finance chief departs ]]> https://www.proactiveinvestors.co.uk/companies/news/212205/silence-therapeutics-finance-chief-departs-212205.html The chief financial officer of Silence Therapeutics PLC (LON:SLN), David Ellam, has left the gene editing specialist with immediate effect.

Silence’s group head of financial planning and analysis, Rob Quinn, will take on Ellam’s responsibilities for the time being whilst a permanent successor is found.

READ: Silence adds new siRNA asset to pre-clinical pipeline

“On behalf of the board I would like to thank David for his contribution to Silence,” said chief executive David Horn Solomon.

“He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.”

]]>
Wed, 09 Jan 2019 07:23:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212205/silence-therapeutics-finance-chief-departs-212205.html
<![CDATA[RNS press release - Departure of Chief Financial Officer ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190109070002_13928147/ Wed, 09 Jan 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20190109070002_13928147/ <![CDATA[News - Silence Therapeutics adds new siRNA asset to pre-clinical pipeline for potential treatment of cardiovascular disease ]]> https://www.proactiveinvestors.co.uk/companies/news/211464/silence-therapeutics-adds-new-sirna-asset-to-pre-clinical-pipeline-for-potential-treatment-of-cardiovascular-disease-211464.html Silence Therapeutics PLC (LON:SLN) has added a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a).

WATCH: Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

David Horn Solomon, of Silence Therapeutics‘ chief executive officer, commented: "We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly-owned assets aimed at addressing areas of significant unmet need.”

He added: “High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing."

“We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk," Solomon concluded.

Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020.

In a note to clients, analysts at ‘house’ broker Peel Hunt said: “We see this as a positive step for the company as new management focus much more on the building the pipeline – adding this to the Silence’s asset for beta-thalassemia and myelodysplastic syndrome (SLN124).”

They added: “We continue to review our valuation methodology following resolution of the recent litigation but this asset will add NPV to the portfolio/platform on a risk-adjusted basis.”

In mid-morning trading, Silence Therapeutics’ shares were 0.7% higher at 55.20p.

 -- Adds analyst comment, share price --

]]>
Wed, 19 Dec 2018 07:57:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211464/silence-therapeutics-adds-new-sirna-asset-to-pre-clinical-pipeline-for-potential-treatment-of-cardiovascular-disease-211464.html
<![CDATA[RNS press release - Silence Therapeutics advances next RNAi medicine ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181219070003_13908820/ Wed, 19 Dec 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181219070003_13908820/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181218163530_13908497/ Tue, 18 Dec 2018 16:35:30 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181218163530_13908497/ <![CDATA[Media files - Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11627/silence-therapeutics-ceo-looks-ahead-to-clinical-trial-next-year-and-prospects-for-rnai-11627.html Fri, 14 Dec 2018 13:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11627/silence-therapeutics-ceo-looks-ahead-to-clinical-trial-next-year-and-prospects-for-rnai-11627.html <![CDATA[News - Silence Therapeutics reaches settlement and licence agreement with Alnylam, ending patent battle ]]> https://www.proactiveinvestors.co.uk/companies/news/210838/silence-therapeutics-reaches-settlement-and-licence-agreement-with-alnylam-ending-patent-battle-210838.html Silence Therapeutics PLC (LON:SLN) announced on Monday that it has reached a settlement and license agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) which resolves all patent legal proceedings between the two firms.

The firm said Alnylam will license patents from Silence and will pay the UK-listed group a tiered royalty on net sales of the US biotech group’s ONPATTRO drug in the EU only ranging from 0.33%to 1.0% through 2023.

WATCH: Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

Silence Therapeutics - a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases – added that all legal proceedings in all jurisdictions between the companies are resolved under the settlement.

David Horn Solomon, Silence Therapeutics’ chief executive officer commented: "We are excited for the potential of ONPATTRO to treat patients with hereditary ATTR amyloidosis polyneuropathy as the first RNAi medicine and are looking forward to following Alnylam's achievements. 

“At Silence Therapeutics we now look forward to focusing on advancing a pipeline of competitive and differentiated medicines that will benefit patients and caregivers."

At the start of October, Silence Therapeutics' long-running patent battle with Alnylam, which was focused on the technology at the heart of ONPATTRO, its first commercial drug, took a new turn when it said European authorities were about to grant a patent further protecting its method of silencing genes via the issue of a notice of intention.

The group also said then that it had applied for an injunction in the Netherlands to prevent Alnylam's ONPATTRO treatment going on sale until a court is able to determine whether the US group has infringed a key patent.

Peel Hunt places rating 'under review'

In a note to clients, analysts at Peel Hunt placed their rating for Silence Therapeutics ‘under review’ and commented: “New management is keen to stress that with risk and cost of litigation now behind it, it can focus on building its pipeline in the near future.

“We had previously included higher, albeit risk-adjusted, royalties (circa 3%-5%) and milestone payments (£7.5mln-£10mln) for the Alnylam settlement but had not included the benefit of Silence’s growing pipeline in the valuation.

“We see today’s news as further validation of the competence that Silence has in RNAi therapeutics but take this opportunity to go to U/R in order to review assumptions with management on the pipeline.”

In early afternoon trading, shares in Silence Therapeutics were 12.8% lower at 75p.

 -- Adds analyst comment, share price --

]]>
Mon, 10 Dec 2018 07:44:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210838/silence-therapeutics-reaches-settlement-and-licence-agreement-with-alnylam-ending-patent-battle-210838.html
<![CDATA[RNS press release - Settlement and License Agreement with Alnylam ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181210070005_13896680/ Mon, 10 Dec 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181210070005_13896680/ <![CDATA[RNS press release - Erratum: Results of Placing - Withdrawn ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181012182932_13827727/ Fri, 12 Oct 2018 18:29:32 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181012182932_13827727/ <![CDATA[RNS press release - Results of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181012171230_13827687/ Fri, 12 Oct 2018 17:12:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181012171230_13827687/ <![CDATA[News - Silence Therapeutics gets one over on Alnylam in ongoing patent battle ]]> https://www.proactiveinvestors.co.uk/companies/news/206892/silence-therapeutics-gets-one-over-on-alnylam-in-ongoing-patent-battle-206892.html Silence Therapeutics PLC (LON:SLN) has been given another boost in its ongoing patent battle with US biotech giant Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).

Alnylam had challenged the validity of five patents recently issued to Silence, and the first of those petitions has been thrown out by US authorities.

READ: The Silence-Alnylam wrangle takes another turn

The US Patent Trial and Appeal Board found that Alnylam, valued at more than US$8bn, had failed to show enough evidence that the claims were invalid.

Silence said the PTAB’s decision not to review the issue of the patent “provides yet another vindication” of the strength of its intellectual property.

Decisions on the remaining patents are due over the next several months.

“We are very pleased with this favourable outcome in US patent office proceedings initiated by Alnylam,” said chief executive David Horn Solomon.

“We are hopeful that the remaining proceedings will result in similar outcomes and that Silence's patent position will be fully vindicated.”

IN-DEPTH: Silence to kick off first clinical trial next year

Earlier this week, Silence told investors that European authorities are close to granting it another patent further protecting its gene silencing technology.

Silence has gone to war with Alnylam and others over the past year or so, claiming that they have been using technology covered by its patents in drugs that silence genes and may be fundamental in the war against cancer.

A court hearing in the UK between Silence and Alnylam – the company behind patisiran, the drug approved by the US Food and Drug Administration earlier this year – is expected to start in the UK in December.

Silence shares were down 1.2% to 120p.

]]>
Thu, 11 Oct 2018 12:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206892/silence-therapeutics-gets-one-over-on-alnylam-in-ongoing-patent-battle-206892.html
<![CDATA[RNS press release - PTAB Upholds Silence Patent ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181011101412_13825076/ Thu, 11 Oct 2018 10:14:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181011101412_13825076/ <![CDATA[News - Silence Therapeutics's Alnylam wrangle takes a new turn ]]> https://www.proactiveinvestors.co.uk/companies/news/206742/silence-therapeutics-s-alnylam-wrangle-takes-a-new-turn-206742.html Silence Therapeutics PLC’s (LON:SLN) patent battle with US biotech Alnylam, which is focused on the technology at the heart of latter’s first commercial drug, took a new turn Wednesday.

The UK group said the European authorities are about to grant a patent further protecting its method of silencing genes by issuing what’s called a notice of intention.

Silence also said it had applied for an injunction in the Netherlands to prevent Alnylam's Onpattro treatment going on sale until a court is able to determine whether the US group has infringed a key patent.

READ: Drug at centre of Silence Therapeutics legal action added to UK Early Access to Medicines Scheme

It said it is also seeking “injunctive relief” in the UK and Portugal.

Chief executive David Horn Solomon said: "Silence continues to innovate with new, competitive RNAi medicines.

“During 2017 and 2018, the European Patent Office has upheld the validity of our expanding patent estate with the granting of additional patents around our foundational chemical modification IP.

“When companies openly promote new product commercialisation in the face of relevant granted patent rights, Silence Therapeutics will take steps to enforce its patents and protect the historic investment made in its technology."

]]>
Wed, 10 Oct 2018 07:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206742/silence-therapeutics-s-alnylam-wrangle-takes-a-new-turn-206742.html
<![CDATA[RNS press release - New divisional patent and injunction application ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181010070005_13822539/ Wed, 10 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181010070005_13822539/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181005141618_13818748/ Fri, 05 Oct 2018 14:16:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20181005141618_13818748/ <![CDATA[RNS press release - Silence to Present at Healthcare Conference ]]> https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20180926070006_13804589/ Wed, 26 Sep 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/909/LSE20180926070006_13804589/